Cognition Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Cognition Therapeutics's earnings have been declining at an average annual rate of -27.3%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.
Belangrijke informatie
-27.3%
Groei van de winst
81.7%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 6.0% |
Inkomstengroei | n/a |
Rendement op eigen vermogen | -135.1% |
Nettomarge | n/a |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?
Sep 06Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease
Jul 31Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
May 22Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
Apr 18Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Nov 30Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
Aug 15Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans
Mar 17Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study
Sep 27We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth
Aug 12Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar
Aug 05We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Mar 19Opbrengsten en kosten
Hoe Cognition Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 0 | -31 | 13 | 45 |
31 Mar 24 | 0 | -29 | 14 | 42 |
31 Dec 23 | 0 | -26 | 14 | 37 |
30 Sep 23 | 0 | -23 | 13 | 32 |
30 Jun 23 | 0 | -23 | 14 | 29 |
31 Mar 23 | 0 | -24 | 14 | 29 |
31 Dec 22 | 0 | -21 | 13 | 30 |
30 Sep 22 | 0 | -24 | 17 | 29 |
30 Jun 22 | 0 | -22 | 14 | 25 |
31 Mar 22 | 0 | -19 | 12 | 21 |
31 Dec 21 | 0 | -16 | 10 | 19 |
30 Sep 21 | 0 | -12 | 5 | 16 |
30 Jun 21 | 0 | -10 | 4 | 16 |
31 Mar 21 | 0 | -9 | 4 | 14 |
31 Dec 20 | 0 | -12 | 5 | 13 |
Kwaliteitswinsten: CGTX is currently unprofitable.
Groeiende winstmarge: CGTX is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: CGTX is unprofitable, and losses have increased over the past 5 years at a rate of 27.3% per year.
Versnelling van de groei: Unable to compare CGTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: CGTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendement op eigen vermogen
Hoge ROE: CGTX has a negative Return on Equity (-135.09%), as it is currently unprofitable.